Aptatek Biosciences Advances PheCheck™ Clinical Validation with Patient Enrollment Underway

Source: BioSpace, by Annalee Armstrong (October 7, 2026). AI-generated summary by biochip.com, published October 8, 2026. Not independently reviewed.

Aptatek Biosciences has begun enrolling patients in a clinical validation study of PheCheck, an investigational home-testing system designed to measure phenylalanine in people with phenylketonuria, or PKU. The prospective study will compare PheCheck results with laboratory analysis of dried blood spot samples. Conducted at Lurie Children's Hospital of Chicago and Boston Children's Hospital, the work is intended to generate evidence for Aptatek's planned U.S. Food and Drug Administration premarket submission. It matters because PKU requires frequent monitoring, while conventional testing can delay results from a centralized laboratory.

Testing a Home System Against Lab Results

PKU is an inherited metabolic condition in which the body cannot properly process the amino acid phenylalanine, often called Phe. People with PKU need to monitor Phe levels as part of managing the condition, and current monitoring commonly requires a blood sample to be sent away for laboratory testing.

PheCheck is designed as a home-based alternative that provides a quantitative Phe result in minutes. Aptatek's system pairs DNA aptamer sensing technology with a reusable electronic reader, a single-use cartridge and a smartphone-connected app. Aptamers are short DNA molecules engineered to bind a particular target, functioning somewhat like a molecular lock designed to recognize a specific key.

How the Validation Study Works

The PheCheck Validation Study, listed as NCT07551921, is expected to enroll about 60 people with PKU who are at least one year old. It is a prospective observational cohort study, meaning investigators will collect and compare results as participants and caregivers use the system rather than assigning participants to a treatment.

At each study visit, participants or caregivers will use a capillary fingerstick blood sample with PheCheck. Investigators will also collect a dried blood spot, or DBS, sample for analysis by a designated laboratory. Comparing the rapid device result with the laboratory reference result will let the team assess how closely PheCheck performs against established testing.

Two Pediatric Centers Lead Enrollment

The study is underway at Ann & Robert H. Lurie Children's Hospital of Chicago and Boston Children's Hospital. Erika Vucko, director of the PKU Clinic at Lurie Children's, and Stephanie Sacharow, director of the Harvey Levy Program for Phenylketonuria and Related Conditions at Boston Children's, serve as the respective site principal investigators.

Vucko said the study will assess PheCheck directly against laboratory reference testing while examining performance when patients and caregivers collect and test fingerstick samples themselves. Sacharow described home Phe monitoring as a longstanding goal for the PKU community and clinicians.

Why This Matters

A home measurement system could potentially shorten the time between collecting a sample and receiving a result. That distinction is important for a condition that requires recurring Phe checks, particularly when samples otherwise travel to laboratories that may be far from the patient.

Still, PheCheck remains investigational. FDA Breakthrough Device Designation can help accelerate interactions with the agency for technologies addressing unmet needs, but it is not FDA clearance or approval. The validation study will provide the clinical comparison data Aptatek plans to use in its regulatory submission, and the system is not commercially available.

PheCheck is the first proposed application of Aptatek's broader HomeCheck platform, which combines a reader, cartridges, assays, software and data systems. For now, the crucial next step is establishing how the PheCheck measurements compare with laboratory testing in the enrolled PKU population.

Start here: What is a biochip?